Navigation Links
Spectral announces 2008 financial results
Date:3/12/2009

ing of year (2,687) (1,021) ---------------------------- Deficit - End of year (4,189) (2,687) ---------------------------- ---------------------------- Basic and diluted loss per common share (0.06) (0.07) ---------------------------- ---------------------------- Weighted average number of common shares outstanding 24,118,424 24,117,333 ---------------------------- ---------------------------- Spectral Diagnostics Inc. Statements of Cash Flows For the years ended December 31, 2008 and 2007 ------------------------------------------------------------------------- (in thousands of dollars) 2008 2007 $ $ Cash provided by (used in) Operating activities Loss and comprehensive loss for the year (1,502) (1,666) Items not affecting cash Amortization 592 536 Amortization of commercial instruments included in cost of sales 76 63 Loss on disposal of property, plant and equipment - 46 Writeoff of purchased technology and trademarks - 66 Stock-based compensation expense 110 117 Interest on convertible note payable 164 165 Changes in non-cash working capit
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
2. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
3. Spectral announces third quarter 2008 results
4. Spectral to bring anti-sepsis therapy to the U.S. market
5. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
8. Spectral and Toray expand collaboration to include new geographic territories
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
11. Spectral announces 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... Inc. (Nasdaq: INSM ), a developer of follow-on ... 23, 2009, NASDAQ issued a notice further extending the suspension ... and those rules requiring a minimum market value of publicly ... through Friday, July 17, 2009, and the original rules will ...
... CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... the completion of patient enrolment in its U.K. ... intravenous administration of REOLYSIN(R) in combination with gemcitabine ... and head and neck. The principal investigators are ...
... 25 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: ... of Shareholders held on Tuesday, March 24, 2009.At the ... of shares of authorized stock (including an increase in ... proposal to increase the number of shares available for ...
Cached Biology Technology:Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
(Date:9/30/2014)... England Journal of Medicine reports positive results of ... against the subset of lung cancer marked by rearrangement ... 50 patients with advanced non-small cell lung cancer testing ... 72 percent, with 3 complete responses and 33 partial ... for the disease to resume its growth after being ...
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... the heels of his discovery in Montana of the first ... Martin has found evidence of more dinosaur burrows this ... Australia. The find, to be published this month in ... dinosaurs of different species, in different hemispheres, and spanned millions ...
... BIRMINGHAM, Ala. The American Heart Association has pledged ... at Birmingham (UAB) biomedical engineering undergraduate students who are ... using hand-held remote controls from the Nintendo Wii video ... Islam and Zach Clark began work on the project ...
... available in German . , Infections ... often caused by bacteria called Pseudomonas aeruginosa. Once they ... virulence factors and can enter into a slimy state, ... of quorum sensing, which cells use to "sense" cell ...
Cached Biology News:Down Under dinosaur burrow discovery provides climate change clues 2Down Under dinosaur burrow discovery provides climate change clues 3UAB students' Nintendo Wii CPR earns American Heart Association support 2A matter of density, not quantity 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... deuterium atoms at the 3, 3', 4, ... use as an internal standard for the ... spectrometry. PGE1 is the theoretical cyclooxygenase metabolite ... virtually undetectable in the plasma of normal ...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: